Results 1 to 10 of about 6,042 (221)

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study [PDF]

Rheumatology and Therapy
Introduction The aim of this work was to evaluate the achievement of minimal clinically important improvement (MCII) in patient-reported outcomes (PROs) with guselkumab among participants with active psoriatic arthritis (PsA) and inadequate response to ...
Laure Gossec, Xenofon Baraliakos, James Galloway, Vilija Oke, Petros Sfikakis, Emmanouil Rampakakis, Mohamed Sharaf, Frederic Lavie, Iain B. McInnes   +8 more
doaj   +2 more sources

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study [PDF]

RMD Open, 2020
Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA).Methods This was a phase II, randomised, placebo-controlled, double-blind trial of adults with active PsA ...
Peter Nash, Atul Deodhar, Philip J Mease, Dafna D Gladman, Philip S Helliwell, Dennis G McGonagle, Alice Gottlieb, Elizabeth C Hsia, Chetan S Karyekar, Wolf-Henning Boehncke, Xie L Xu, Stephen Xu   +11 more
doaj   +4 more sources

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors [PDF]

Rheumatology and Therapy
Introduction There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (
Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola   +13 more
doaj   +2 more sources

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial [PDF]

Lancet, The, 2020
Background: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 subunit, significantly and safely improved psoriatic arthritis in a ...
Proton Rahman, Alice B Gottlieb
exaly   +3 more sources

Guselkumab Treatment ADHEREnce in BulGaria of Patients with Psoriasis—ADHERE-BG Study [PDF]

Dermatology and Therapy
Introduction Treatment adherence is crucial for managing chronic diseases, including plaque psoriasis. In Bulgaria, patients with plaque psoriasis can receive treatment with reimbursed biologics, such as guselkumab, if they meet National Health Insurance
Grisha S. Mateev, Zdravka V. Demerdjieva, Rumyana K. Yankova, Klimentina D. Gospodinova, Boryana E. Ilieva, Razvigor B. Darlenski   +5 more
doaj   +2 more sources

Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials [PDF]

Rheumatology and Therapy
Introduction Psoriatic arthritis (PsA) is a heterogeneous disease, and clinical manifestations can differ between sexes. Sex-disaggregated baseline characteristics, guselkumab efficacy, and radiographic progression were assessed in a pooled cohort of ...
Dafna D. Gladman, Lihi Eder, Carlo Selmi, Philip J. Mease, Alexis Ogdie, Karissa Lozenski, Elizabeth Adamson, Mohamed Sharaf, Emmanouil Rampakakis, Laura Pina Vegas, Laura C. Coates   +10 more
doaj   +2 more sources

Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) [PDF]

Dermatology and Therapy
Introduction Guselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA).
Mario Valenti, Luciano Ibba, Sara Di Giulio, Paolo Dapavo, Piergiorgio Malagoli, Angelo V. Marzano, Francesco Loconsole, Martina Burlando, Anna Balato, Valentina Dini, Matteo Megna, Giampiero Girolomoni, Emanuele Trovato, Claudia Lasagni, Massimo Travaglini, Claudio Guarneri, Nicola Zerbinati, Simone Ribero, Francesca M. Gaiani, Carlo G. Carrera, Emanuele C. Cozzani, Eugenia V. Di Brizzi, Alessandra Michelucci, Luca Potestio, Martina Maurelli, Martina Dragotto, Luca Mastorino, Eleonora Bongiovanni, Francesco Messina, Andrea Sechi, Rossana Moroni, Antonio Costanzo, Alessandra Narcisi   +32 more
doaj   +2 more sources

Guselkumab - In Psoriasis and Beyond

Dermatology Practical & Conceptual
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis.
Aditya Kumar Bubna, Vinayak Viplav
doaj   +3 more sources

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study

Indian Journal of Dermatology
Background: Overweight and obesity are common in patients with psoriasis and are associated with increased disease severity and declined treatment response.
Xiuqiu Lin, Min Ou, Yang Li, Junjie Lin, Yunling Yan, Xiaohua Wang   +5 more
doaj   +2 more sources

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis

Clinical and Translational Science, 2022
Guselkumab is an anti‐interleukin‐23 human monoclonal antibody effective in treating psoriatic arthritis (PsA). To characterize the pharmacokinetics (PKs) and exposure‐response relationship of guselkumab in PsA, population PKs, and exposure‐response ...
Yang Chen, Xin Miao, Chyi‐Hung Hsu, Yanli Zhuang, Alexa Kollmeier, Zhenhua Xu, Honghui Zhou, Amarnath Sharma   +7 more
doaj   +1 more source